Objectives: The purpose of this study was to investigate the association between prophylactic antibiotic administration (PAA) and postoperative infection after radical cystectomy with urinary diversion in patients with invasive bladder cancer. Methods: Forty-nine consecutive cases were analyzed prospectively. Postoperative infections were categorized as surgical site infection (SSI) and remote infection (RI). We used the antibiotics tazobactam/piperacillin (TAZ/PIPC) as PAA (48 h). Results: A total of 18 (36.7%) patients had postoperative infections, 4/18 (22.2%) patients had wound infections, and 12/18 (66.7%) patients had RI. In the risk factor study for SSI and RI occurrences, we found that the surgical time was significantly shorter in the non-infection group (p = 0.031). Taken together, these results suggest that TAZ/PIPC with shorter PAA duration (48 h) might lead to a lower rate of postoperative infections. Conclusions: Our data showed that PAA with TAZ/PIPC with a shorter duration PAA (48 h) might be recommended for RC with urinary diversion. We found that the surgical time was significantly shorter in the non-infection group. A prospective study based on our data is desirable to establish or revise PAA strategy for prophylactic medication to prevent postoperative infection after RC with urinary diversion.

Keywords:
Prophylactic antibiotic administration, Radical cystectomy with urinary diversion, Tazobactam/piperacillin, Surgical site infection and remote infection
1.
Koie T, Yamamoto H, Okamoto A, Imai A, Iwabuchi I, Yoneyama T, et al. [Risk factors for surgical site infection in radical cystectomy: efficacy of buried suture by absorbable thread for skin closure].
Hinyokika Kiyo
. 2009 Feb; 55(2): 75–8.
2.
Hara N, Kitamura Y, Saito T, Komatsubara S, Nishiyama T, Takahashi K. Perioperative antibiotics in radical cystectomy with ileal conduit urinary diversion: efficacy and risk of antimicrobial prophylaxis on the operation day alone.
Int J Urol
. 2008 Jun; 15(6): 511–5.
3.
Yamamoto S, Shigemura K, Kiyota H, Wada K, Hayami H, Yasuda M, et al.; Japanese Research Group for UTI. Essential Japanese guidelines for the prevention of perioperative infections in the urological field: 2015 edition.
Int J Urol
. 2016 Oct; 23(10): 814–24.
4.
Urologic Surgery Antimicrobial Prophylaxi [cited 2018 July 8]. Available from: http://www.auanet.org/guidelines/antimicrobial-prophylaxis-(2008-reviewed-and-validity-confirmed-2011-amended-2012)
5.
Guidelines on Urological Infections [cited 2018 July 8]. Available from: https://uroweb.org/wp-content/uploads/17_Urological-infections_LR-II.pdf
6.
Matsumoto T, Kiyota H, Matsukawa M, Yasuda M, Arakawa S, Monden K; Japanese Society of UTI Cooperative Study Group (Chairman; Tetsuro Matsumoto). Japanese guidelines for prevention of perioperative infections in urological field.
Int J Urol
. 2007 Oct; 14(10): 890–909.
7.
Pourmand G, Abedi AR, Karami AA, Khashayar P, Mehrsai AR. Urinary infection before and after prostatectomy.
Saudi J Kidney Dis Transpl
. 2010 Mar; 21(2): 290–4.
8.
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR; Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Guideline for prevention of surgical site infection, 1999.
Am J Infect Control
. 1999 Apr; 27(2): 97–132.
9.
Quek ML, Stein JP, Daneshmand S, Miranda G, Thangathurai D, Roffey P, et al. A critical analysis of perioperative mortality from radical cystectomy.
J Urol
. 2006 Mar; 175(3 Pt 1): 886–9.
10.
Esposito S. Immune system and surgical site infection.
J Chemother
. 2001 Nov; 13(Spec No 1): 12–6.
11.
Wullt B, Holst E, Steven K, Carstensen J, Pedersen J, Gustafsson E, et al. Microbial flora in ileal and colonic neobladders.
Eur Urol
. 2004 Feb; 45(2): 233–9.
12.
Lara-Isla A, Medina-Polo J, Alonso-Isa M, Benítez-Sala R, Sopeña-Sutil R, Justo-Quintas J, et al. Urinary Infections in Patients with Catheters in the Upper Urinary Tract: microbiological Study.
Urol Int
. 2017; 98(4): 442–8.
13.
Takeyama K, Matsukawa M, Kunishima Y, Takahashi S, Hotta H, Nishiyama N, et al. Incidence of and risk factors for surgical site infection in patients with radical cystectomy with urinary diversion.
J Infect Chemother
. 2005 Aug; 11(4): 177–81.
14.
Kanamaru S, Terai A, Ishitoya S, Kunishima Y, Nishiyama H, Segawa T, et al. Assessment of a protocol for prophylactic antibiotics to prevent perioperative infection in urological surgery: a preliminary study.
Int J Urol
. 2004 Jun; 11(6): 355–63.
15.
Shigemura K, Tanaka K, Matsumoto M, Nakano Y, Shirakawa T, Miyata M, et al. Post-operative infection and prophylactic antibiotic administration after radical cystectomy with orthotopic neobladder urinary diversion.
J Infect Chemother
. 2012 Aug; 18(4): 479–84.
16.
Hamasuna R, Betsunoh H, Sueyoshi T, Yakushiji K, Tsukino H, Nagano M, et al. Bacteria of preoperative urinary tract infections contaminate the surgical fields and develop surgical site infections in urological operations.
Int J Urol
. 2004 Nov; 11(11): 941–7.
17.
Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate.
J Urol
. 2010 Sep; 184(3): 990–4.
18.
Kyoda Y, Takahashi S, Takeyama K, Masumori N, Tsukamoto T. Decrease in incidence of surgical site infections in contemporary series of patients with radical cystectomy.
J Infect Chemother
. 2010 Apr; 16(2): 118–22.
19.
Wolters M, Oelke M, Lutze B, Weingart M, Kuczyk MA, Chaberny IF, et al. Deep Surgical Site Infections after Open Radical Cystectomy and Urinary Diversion Significantly Increase Hospitalisation Time and Total Treatment Costs.
Urol Int
. 2017; 98(3): 268–73.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.